Английская Википедия:Ibodutant

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. Шаблон:As of, it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.[1]

See also

References

Шаблон:Reflist

Further reading

Шаблон:Refbegin

Шаблон:Refend

Шаблон:Neurokinin receptor modulators


Шаблон:Nervous-system-drug-stub